Cointime update: The U.S. Food and Drug Administration has required makers of major GLP-1 drugs including Ozempic and Zepbound to add a warning label for non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause permanent vision loss. FDA data show about 6 NAION cases per 100,000 people taking the drugs each year.
FDA Adds Rare Blindness Risk Warning to GLP-1 Drugs Including Ozempic, Zepbound
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
1h ago
House Democrats Target Trump Inner Circle in First Oversight Requests
1h ago
US Democrats Plan Data Center Power Reform, Operators May Pay $35B More Over 10 Years
1h ago
Democrats to Probe Trump’s $100B Venezuela Oil Deal
3h ago
UBS Global Wealth Management Forecasts S&P 500 at 8,200 by End-2027
3h ago
Tencent Q3 2026 Revenue Rises 8% to RMB 207.3 Billion
3h ago
Onshore yuan closes at 6.6653 per dollar, up 2 pips